The National Immunisation Advisory Committee (NIAC) will meet to consider further possible recommendations on the use of the AstraZeneca Covid-19 vaccine.
Many EU countries have introduced age restrictions on the use of the vaccine, limiting its use to older people. It follows the European Medicines Agency's finding last week, of a possible link between the AstraZeneca vaccine and rare blood clotting issues in adults who received it.
Last week, NIAC said that the overall benefit of the highly-effective vaccine, in protecting people from severe Covid-19 disease, hospitalisation and death, outweighed the risks of this very rare event.